A Biden-appointed federal judge has ordered the Trump administration to justify its new testosterone screening program for male troops while simultaneously arguing that hormone treatment disqualifies transgender service members, a legal challenge that could complicate the Pentagon's defense of its transgender troop ban.
U.S. District Judge Ana Reyes, who sits on the bench in Washington, D.C., issued a written order Wednesday directing both sides in the ongoing case Talbott v. Trump to explain the "basis for treating trans men and other service members differently between this new policy and the Military Ban." The order lands squarely on a tension the administration created for itself: Defense Secretary Pete Hegseth's new testosterone replacement therapy initiative for male service members and the executive order banning transgender troops rely on opposite assumptions about whether routine hormone treatment belongs in the military.
The Pentagon now has until an August 7 hearing to answer the judge's questions, about cost, medical logistics, and the legal rationale for drawing a line between the two policies.
Earlier this month, Hegseth announced that male service members aged 30 and older would undergo annual screenings for testosterone deficiency. Those with lower-than-normal levels could volunteer for testosterone replacement therapy. Troops under 30 could also participate voluntarily, AP News reported. Hegseth framed the program as a readiness measure, calling it necessary to allow troops to operate at their "absolute best."
In a video posted on X from his @SecWar account, Hegseth described the initiative as building "the High-T department of war", a nod to President Trump's rebranding of the Defense Department. The screening policy fits within Hegseth's broader push to refocus the military on physical fitness and combat readiness.
"By addressing these health markers early, we're keeping you on the leading edge of lethality."
That was Hegseth's pitch. And on its own terms, the idea has merit. A military that prioritizes the physical readiness of its fighting force is doing exactly what taxpayers expect. The problem is what the policy implies when set beside the administration's other position on hormone treatment.
Trump's executive order banning transgender troops rests on a specific argument: that the Armed Forces require members who can meet high physical and mental health standards "without the benefit of routine medical treatment or special provisions." Judge Reyes quoted that language directly in her order. Then she pointed to the new TRT program, which is, by definition, routine medical treatment, and asked the obvious question.
The judge ordered both parties to address "the similarities and differences in administering TRT, both medically and logistically, for trans men compared to other service members, including cis individuals," Breitbart reported. She also directed the government to prepare briefs addressing the Supreme Court's ruling in B.P.J. v. West Virginia and its implications for the transgender troops executive order, according to the Washington Examiner.
Reyes, a Biden appointee, oversees at least two lawsuits challenging the administration's ban on and removal of transgender troops. The case docket for Talbott v. Trump is publicly available through federal court records.
This is not the first time a federal judge has challenged Hegseth's Pentagon in court. But this order is different in kind. It does not block a policy. It asks the administration to reconcile two policies that appear to contradict each other on a foundational point.
The core difficulty for the Pentagon is straightforward. The transgender troop ban argues that service members who need ongoing hormone treatment cannot meet military standards. The TRT initiative creates a new program of ongoing hormone treatment for potentially thousands of service members and calls it a readiness enhancer.
The Trump administration has previously argued against hormone-related treatments for transgender military members by citing cost, monitoring requirements, and the risk that troops on such regimens could become non-deployable. Those same objections now apply, at least on paper, to the TRT program Hegseth just launched.
Meanwhile, the Pentagon has balked at the cost of gender-related hormone treatment for transgender troops even as it rolls out a testosterone program whose cost figures have not been publicly disclosed. No specific price tag for the TRT initiative appears in any public reporting so far.
Medical experts have also raised concerns about the screening program itself. Doctors cited by Reuters warned that testosterone replacement therapy could increase risks to service members' fertility and cause other long-term health problems. Those warnings sit uneasily beside Hegseth's framing of the program as a straightforward health optimization measure.
The court order arrives during a stretch in which Hegseth has faced scrutiny from several quarters. Congressional Republicans have pressed him on Pentagon funding and war costs in recent hearings, and his tenure has featured a series of public confrontations over policy and personnel.
None of that changes the merits of the testosterone initiative or the transgender troop ban considered separately. Conservatives have long argued, correctly, that military readiness should not be subordinated to social policy, and that the armed forces exist to fight and win wars, not to serve as a vehicle for identity politics. The TRT program reflects that principle. So does the position that troops must meet demanding physical and mental standards without special medical accommodations.
The problem is that those two positions now sit in tension with each other, and a federal judge has noticed. The administration cannot simultaneously argue that routine hormone therapy is a readiness tool for one group and a disqualifying dependency for another without offering a clear medical and legal distinction between the two. If the Pentagon has that distinction, the August 7 hearing is the place to make it.
Hegseth has shown a willingness to fight for his vision of a leaner, tougher military. He has challenged DEI programs at West Point, pushed fitness standards, and clashed publicly with critics over defense readiness. That combativeness has served him well in the political arena. In a courtroom, though, consistency matters more than conviction, and right now, the Pentagon's own policies are arguing with each other.
Good policy should be able to survive its own logic. If the administration's testosterone program and its transgender troop ban both rest on sound reasoning, the Pentagon ought to welcome the chance to explain why. If the explanation does not hold up, the fault lies not with the judge who asked the question but with the officials who did not think it through before announcing the policy on social media.